Security teams are forced to rely on network-level controls, segmentation, and detection techniques because installing normal security agents on certified medical devices may not be possible. That limitation leaves attackers with more room to hide if defenses depend only on endpoint tooling. Deception helps narrow that gap by creating traps that reveal hostile activity without modifying the device itself.
Why legacy medical devices change the security model
legacy medical device often cannot run standard endpoint agents because of certification constraints, vendor support limits, or the risk of altering validated software behaviour. That changes the defence model from host-based enforcement to compensating controls around the device. In practice, security teams have to assume weaker local visibility and build protection from the network, the identity of connected systems, and the behaviour of traffic around the device.
That shift matters because many common endpoint assumptions no longer hold. You cannot rely on a sensor being present to detect tampering, enumerate processes, or block suspicious activity on the device itself. The result is not “no security,” but a different control set that has to absorb more responsibility for segmentation, monitoring, and response.
How network-level controls compensate for missing endpoint tooling
When direct control is unavailable, the network becomes the enforcement point. Segmentation limits which systems can talk to the device, reduces lateral movement, and contains compromise if the device is abused. Detection then depends on traffic patterns, protocol anomalies, asset baselines, and alerting on unexpected connections rather than on host telemetry. That is why the same device may be survivable in a tightly segmented environment and far more exposed on a flat network.
Deception adds value because it creates visibility where the device itself cannot. Honeypots, decoys, or trap services can reveal reconnaissance, unauthorized access attempts, and abnormal operator behaviour without changing the certified device. For this setting, deception is not a replacement for segmentation or access restriction, but a way to surface hidden activity that endpoint tooling would normally catch.
- Use segmentation to define who and what may reach the device.
- Baseline expected communications and alert on deviations.
- Place decoys where they are likely to attract misuse or scanning.
- Treat unexpected device-to-device or device-to-internet paths as high-signal events.
Why attackers benefit from blind spots on certified devices
Legacy devices are attractive because defenders often have fewer levers to pull once the device is deployed. If the device cannot be instrumented, attackers can focus on network access, adjacent systems, or weak operational controls around the device rather than on the device itself. That makes the surrounding environment, including gateways, management stations, and remote support paths, part of the attack surface.
The practical consequence is that compromise can hide longer if defenders depend only on endpoint telemetry. Network-based monitoring and deception are therefore not optional extras in high-risk environments; they are often the only way to preserve some detection capability without disturbing the device. Healthcare teams should expect this limitation to persist wherever safety certification and operational continuity outweigh software changes.
Risk and Threat Considerations
Security exposure increases when organisations assume a certified device can be protected like a modern endpoint. The main risk is not only weaker prevention, but weaker detection and slower containment if the device, its management path, or a neighbouring system is abused.
Failure mechanism: Attackers exploit the absence of host telemetry by pivoting through allowed network paths, abusing remote administration channels, or hiding activity in normal-looking protocol traffic. Without segmentation and deception, defenders may not see the misuse until the device is already part of a broader incident.
Impact: The result can be covert persistence, broader network movement, or loss of confidence in clinical systems that cannot be quickly reimaged or instrumented. In healthcare, that also raises operational risk because containment choices may be limited by patient care and device availability.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
CIS Controls v8 and NIST SP 800-53 Rev 5 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| CIS Controls v8 | CIS-12 — Network Infrastructure Management | Segmentation and traffic control are central when endpoint agents cannot run. |
| CIS-8 — Audit Log Management | Detection here depends on network and management logging rather than host agents. | |
| Recommendation — Segment device networks and restrict allowed communication paths to shrink attack surface. Centralize and review logs from gateways, firewalls, and management paths for anomalous device activity. | ||
| NIST SP 800-53 Rev 5 | SC-7 — Boundary Protection | Boundary controls are the main compensating control when endpoint enforcement is unavailable. |
| AU-6 — Audit Record Review, Analysis, and Reporting | Network-based detection needs systematic analysis because the device itself may not log effectively. | |
| SI-4 — System Monitoring | Compensating monitoring is required when the endpoint cannot host security tooling. | |
| Recommendation — Enforce boundary filtering and segmentation around certified devices and their supporting systems. Review network and access logs for unexpected connections, protocol drift, and suspicious management activity. Monitor device-adjacent traffic and alert on deviations from the approved communications baseline. | ||
Practitioner Guidance
What to prioritise: Start with device isolation, not with detection tuning. If you cannot run an agent, the first question is whether the device’s communications can be reduced to a small, well-understood set of approved peers and protocols.
What to verify: Confirm that your monitoring stack can distinguish expected medical-device traffic from management traffic, vendor support traffic, and anything that should never appear. If you cannot explain those paths, you do not yet have a usable control baseline.
Decision rule: If the device cannot be instrumented, treat every unexpected connection as a potential compromise signal and use deception to increase confidence in what “normal” looks like. If the device can be segmented but not fully monitored, assume prevention and early warning must come from the surrounding network, not the endpoint.
Practitioner takeaway: For legacy medical devices, the goal is not to force endpoint-style security onto an untouchable asset, but to make the network and surrounding controls strong enough that hidden activity becomes difficult to sustain.
Related resources from NHI Mgmt Group
- What breaks when healthcare organisations try to secure medical devices with legacy segmentation approaches?
- What happens when organisations try to support telework without secure remote access controls?
- What happens when end-to-end encryption is used without secure key management and endpoint controls?
- What happens when agencies try to defend email with legacy secure email gateway approaches instead of modern behavioral controls?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 26, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
